Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1450 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland. Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
FDA Okays Redhill Talicia (Sydney's Heliconda) For H. Pylori Dr Boreham's Crucible: Visioneering Technologies
Botanix Falls 48% As Cannabinoid BTX1503 Misses Acne Endpoint Clinuvel Up 63% On FDA Scenesse For EPP Approval Antisense Jumps 100% On ATL1102 'Positive Drug Effect For DMD'
YTD: BDI-40 Up 114%, ASX200 21%, Big Caps 56%
December 2, 2019 The benchmark ASX200 rose 20.8 percent for the 12-months, with the collective value of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) up 55.9 percent to $173,845 million.
The Nasdaq Biotechnology Index (NBI) continued its recovery, up 11.4 percent for the year to November 30 and 9.5 percent for the month of November.
For the month of November, the ASX200 was up 2.7 percent, the BDI-40 was up 0.2 percent; and the Big Caps improved 9.3 percent.
Both Cochlear and CSL improved 10.5 percent in November, to market capitalizations of $13,517 million and $128,440 million, respectively, with Resmed up 4.5 percent to a $31,888 million, all in record territory.
Twenty-six of the BDI-40 stocks were up, with 17 up more than 10 percent and 11 up more than 20 percent. Thirteen companies fell, with six down by more than 10 percent.
The generally smaller capitalization Second 20 put on the best performances, led by Imugene up $74 million or 87.1 percent to $159 million, followed by Oncosil (77.3%), Kazia (70.4%), Prescient (54.5%), Resonance (52.8%), Actinogen (35.1%), Genetic Signatures (31.4%), Paradigm (30.6%), Dimerix (23.5%), Impedimed (22.5%), Pharmaxis (20.3%), Avita (18.8%), Medical Developments (17.2%), Universal Biosensors (16.1%), Proteomics (15.4%) and Starpharma (13.7%).
Opthea led the falls, ahead of today’s discounted $50 million capital raising, down $115 million or 22.0 percent to $683 million, followed by Antisense (21.4%), Polynovo (17.3%), Cynata (12.7%), Orthocell (12.0%), Immutep (9.2%), LBT (8.3%) and Pro Medicus (6.6%).
Outside the BDI-40, Bluechiip, Memphasys, Phylogica, Resapp and Somnomed were at 12-month highs, with Alcidion and Painchek down from their September 30 peaks. Mayne Pharma continued to ease, down 10.1 percent in November to $738 million and down 52.2 for the year to November 30.
The 18 Cannabis Corner companies mislaid a further 16.2 percent in November, to a collective value of less than $1 billion from the illusory high of $1,913 million on July 31, 2019, to the lowest level since November 30, 2017. Four were up, 12 fell and two were unchanged.
The only significant rise was Palla Pharma (formerly Tasmanian Poppy Industries Enterprises), up 28.6 percent to $1.08 million, which markets opiates as well as marijuana.
In the US, Israel’s Redhill with Australian assets was up 4.4 percent to $358 million Eyepoint (Psivida) fell 29.0 percent to $247 million, and Queensland’s Protagonist lost 31.4 percent to $351 million.
BDI-40 v S&P ASX200 Jun 30, 2006 to Nov 30, 2019
 3-Year Big Caps (Cochlear, CSL, Resmed) to Nov 30, 2019
 BDI-40 ($m) v S&P ASX200 – Year to Nov 30, 2019 (current, raw data)
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At Nov 30, 2019
* Biotech Daily editor, David Langsam, owns shares in Acrux, Alterity, Amplia, Cynata, Mesoblast
Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in.